Carmell Therapeutics closes acquisition of Elevai Skincare
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2025
0mins
Acquisition Announcement: Carmell Corporation has completed the acquisition of Elevai Skincare's skin and hair care business, which specializes in physician-dispensed exosome products, through a definitive purchase agreement with PMGC Holdings and Elevai.
Financial Details: The acquisition involved approximately $1.1 million worth of Carmell common stock and an additional $57,000 in cash for specified inventory, with some shares held back for indemnification purposes for 12 months post-closing.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
